The work of F. Stephen Hodi et al. (Hodi et al., 2010) showed that blocking the CTLA-4 (cytotoxic T-lymphocyte–associated antigen 4) Immune Checkpoint Pathway can be used in the treatment of metastatic melanoma. This evidence concerns the gene CTLA4 and metastatic melanoma.